HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation

Blood

Volumn 124, Issue 26, 2014, Pages 3996-4003

  Petersdorf, Effie W ^a,b   Gooley, Theodore A ^a   Malkki, Mari ^a   Bacigalupo, Andrea P ^c   Cesbron, Anne ^d   Du Toit, Ernette ^e   Ehninger, Gerhard ^f   Egeland, Torstein ^g   Fischer, Gottfried F ^h   Gervais, Thibaut ⁱ   Haagenson, Michael D ^j   Horowitz, Mary M ^k   Hsu, Katharine ^l   Jindra, Pavel ^m   Madrigal, Alejandro ⁿ   Oudshoorn, Machteld ^o   Ringdén, Olle ^p   Schroeder, Marlis L ^q   Spellman, Stephen R ^j   Tiercy, Jean Marie ^r   Velardi, Andrea ^s   Witt, Campbell S ^t   O'Huigin, Colm ^u   Apps, Richard ^u,v   Carrington, Mary ^u,v   more..

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j Statistical Center for International Blood and Marrow Transplant Research   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q UNIVERSITY OF MANITOBA   (Canada)

^r GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^s UNIVERSITY OF PERUGIA   (Italy)

^t ROYAL PERTH HOSPITAL   (Australia)

^u SAIC FREDERICK INC   (United States)

^v MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN;

ADOLESCENT; ADULT; AGED; ALLELE; ALLOTYPE; ANTIGEN EXPRESSION; ARTICLE; CELL TRANSPLANTATION; CHILD; FEMALE; FLUORESCENCE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; ORGAN DONOR; OUTCOME ASSESSMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LEUKEMIA; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA-C ANTIGENS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNRELATED DONORS; YOUNG ADULT;

EID: 84919465848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599969     Document Type: Article

References (35)

1. Dausset J. Leuco-agglutinins IV: leuco-agglutinins and blood transfusion. Vox Sang. 1954;4:190-198.
2. Van Rood JJ, Van Leeuwen A. Leukocyte grouping. A method and its application. J Clin Invest. 1963;42:1382-1390.
3. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25):1794-1800.
4. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206.
5. Heemskerk MB, Roelen DL, Dankers MK, et al. Allogeneic MHC class I molecules with numerous sequence differences do not elicit a CTL response. Hum Immunol. 2005;66(9):969-976.
6. Lee SJ, Klein J, Haagenson M, et al. Highresolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13): 4576-4583.
7. Woolfrey A, Klein JP, Haagenson M, et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):885-892.
8. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 1987; 329(6139):512-518.
9. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood. 2001;98(10):3150-3155.
10. Kawase T, Morishima Y, Matsuo K, et al; Japan Marrow Donor Program. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235-2241.
11. Marino SR, Lin S, Maiers M, et al. Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(2):217-226.
12. Pidala J, Wang T, Haagenson M, et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013;122(22):3651-3658.
13. Little AM, Parham P. Polymorphism and evolution of HLA class I and II genes and molecules. Rev Immunogenet. 1999;1(1):105-123.
14. Archbold JK, Macdonald WA, Burrows SR, Rossjohn J, McCluskey J. T-cell allorecognition: a case of mistaken identity or déjàvu? Trends Immunol. 2008;29(5):220-226.
15. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
16. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100(10):3825-3827.
17. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105(12):4878-4884.
18. Farag SS, Bacigalupo A, Eapen M, et al; KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12(8):876-884.
19. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11):5058-5061.
20. Morishima Y, Yabe T, Matsuo K, et al; Japan Marrow Donor Program. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007;13(3):315-328.
21. Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008;14(9 Suppl):37-44.
22. Apps R, Qi Y, Carlson JM, et al. Influence of HLA-C expression level on HIV control. Science. 2013; 340(6128):87-91.
23. Thomas R, Apps R, Qi Y, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet. 2009; 41(12):1290-1294.
24. Fernandez-Viña MA, Wang T, Lee SJ, et al. Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood. 2014;123(8):1270-1278.
25. Pidala J, Lee SJ, Ahn KW, et al. Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood. 2014.
26. Petersdorf EW, Malkki M, Hsu K, et al; International Histocompatibility Working Group in Hematopoietic Cell Transplantation. 16th IHIW: international histocompatibility working group in hematopoietic cell transplantation. Int J Immunogenet. 2013;40(1):2-10.
27. Kulkarni S, Qi Y, O'hUigin C, et al. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci USA. 2013;110(51):20705-20710.
28. Robinson J, Halliwell JA, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 2013;41(Database issue): D1222-D1227.
29. World Health Organization. WHO HLA nomenclature. Available at http://hla.alleles.org/wmda/index.html. Accessed March 15, 2013.
30. Stranger BE, Forrest MS, Clark AG, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1(6):e78.
31. Fellay J, Shianna KV, Ge D, et al. A wholegenome association study of major determinants for host control of HIV-1. Science. 2007; 317(5840):944-947.
32. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-562.
33. Fischer JC, Ottinger H, Ferencik S, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol. 2007;178(6):3918-3923.
34. Joncker NT, Shifrin N, Delebecque F, Raulet DH. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010;207(10):2065-2072.
35. Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010; 207(10):2073-2079.